Shukun Technology Snares ￥200M in Series B1 Financing

According to VCBeat, recently, Shukun Technology, an AI company in healthcare, announced the completion of a ￥200 million Series B1 financing, led by BOC International Holdings, with participation from Jianxing Medical Fund under the management of CCB International, and existing shareholders including CCV Capital and Huagai Capital. 

The fund raised will be used to improve the company's leading strength in the heart, nervous system, tumor and other fields, build new medical infrastructure, accelerate the implementation of new AI technology in hospitals at all levels.

Founded in June 2017 and headquartered in Beijing, Shukun Technology began to explore the application of AI technology in healthcare and started to do researches on cardiovascular diseases. 

In the past few years, Shukun Technology has made many achievements. In March 2019, the analysis software used in the diagnosis of coronary stenosis with CT angiography developed by the company passed the special approval procedure of innovative medical devices and entered the green channel of innovation approval in China. In May 2019, Several AI-powered products for heart, head and neck, and the first multicentre result comparing AI with gold standard were released globally by Shukun Technology, which aroused widespread discussion in the industry.

Ma Chune, CEO of Shukun Technology, said, "Artificial intelligence is one of the key tools to address the shortage of doctors, but in 2017, entrepreneurs preferred to focus on applications in pulmonary tuberosity imaging which is easier, while few exploring in heart CT. "Difficult access to cardiac imaging data and the lack of open source models were the main reasons that kept AI companies from R&D on the cardiovascular system. Secondly, the post-processing of 3D heart imaging is much more difficult than 2D lung nodule imaging." 

Up to now, The AI-based products of Shukun Technology not only covers the simple heart CT processing, but also the diagnosis of cerebrovascular disease. In addition to the existing CT-FFR measurement system and the auxiliary diagnosis system for aorta, Shukun has also developed the head and neck CT auxiliary diagnosis system, expanding the application of AI in the cardiovascular system to the whole system of blood vessels. 

BOCI is a wholly-owned subsidiary of Bank of China Ltd. BOCI is well-positioned to offer its clients a wide range of investment banking services, including securities underwriting, mergers & acquisitions, financial advisory, equity sales & trading, equity derivatives, fixed income, asset management, private equity investments and global commodities.

CCB International (Holdings) Limited and its subsidiaries (CCB International) is an investment services flagship which is owned by China Construction Bank Corporation ("CCB"). Its core business is divided into three main areas, namely Pre-IPO, IPO and Post-IPO which in turn form a comprehensive investment services value chain.